

WHAT IS CLAIMED IS:

1. A method of screening for neuropathology in an individual comprising the steps of:
  - a) obtaining a fluid sample from the individual;
  - b) contacting the sample with an antibody specifically immunoreactive with ICAM-4;
  - c) quantitating the level of ICAM-4/antibody binding in the sample; and
  - d) comparing the level of ICAM-4/antibody binding in the sample to the level of ICAM-4/antibody binding in individuals known to be free of neuropathology.
2. The method of claim 1 wherein the fluid sample is serum.
3. The method of claim 1 wherein the fluid sample is plasma.
4. The method of claim 1 wherein the fluid sample is cerebrospinal fluid.
5. The method of claim 1 wherein the ICAM-4/antibody binding is quantitated by radioimmunoassay (RIA).
6. The method of claim 1 wherein the ICAM-4/antibody binding is quantitated by enzyme-linked immunosorbent assay (ELISA).
7. The method according to any one of claims 1 through 6 wherein the neuropathology is epilepsy.
8. The method according to any one of claims 1 through 6 wherein the neuropathology is dementia associated with AIDS progression.

9. The method according to any one of claims 1 through 6 wherein the neuropathology is Alzheimer's disease.

10. The method according to any one of claims 1 through 6 wherein the neuropathology is a cortical dementia.

11. The method according to claim 10 wherein the cortical dementia is selected from the group consisting of Pick's disease, diffuse cortical Lewy body disease, and frontal lobe degeneracy.

12. The method according to any one of claims 1 through 6 wherein the neuropathology is a subcortical dementia.

13. The method according to claim 12 wherein the subcortical dementia is selected from the group consisting of Parkinson's disease, Huntington's disease, and progressive supranuclear.

14. The method according to any one of claims 1 through 6 wherein the neuropathology is a primary psychiatric disorder.

15. The method according to claim 14 wherein the primary psychiatric disorder is selected from the group consisting of depression, schizophrenia and psychosis.

16. The method according to any one of claims 1 through 6 wherein the neuropathology is a nongenetic dementia.

17. The method according to claim 16 wherein the nongenetic dementia arises from a condition selected from the group consisting of infection, vasculitis, a metabolic disorder, a nutritional disorder, a vascular disorder, toxic encephalopathies, and tumors.